Business
POLB 001 LPS Challenge Trial Paper Published
Poolbeg Pharma PLC has announced the publication of peer-reviewed data from its POLB 001 LPS challenge trial in Frontiers in Immunology, confirming that POLB 001 significantly reduced key inflammatory biomarkers and immune cell recruitment, including neutrophils by 72.4%-81.5% and TNF by 35.3%-65.1%, while being safe and well-tolerated across all dose levels. The study validates POLB 001's potent inhibition of p38 MAPK driven cytokine responses and supports its potential to prevent cancer immunotherapy-induced Cytokine Release Syndrome, with interim data from the TOPICAL trial anticipated this summer. Disclaimer*
About this update from Poolbeg Pharma Plc
[{"type":"text","content":"\n\n\n \nPoolbeg Pharma plc\n \nPeer-Reviewed POLB 001 LPS Challenge Trial Paper Published in Frontiers in Immunology\n \n28 January 2026- Poolbeg Pharma (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces the publication of a peer-reviewed paper from the POLB 001 LPS human challenge trial in Frontiers in Immunology. Key conclusions from the paper include:\n \n\n\n\n\n· \n\n\nPOLB 001 significantly reduced key inflammatory biomarkers and immune cell recruitment following LPS challenge in healthy volunteers\n\n\n\n\n· \n\n\nPOLB 001 was safe and well tolerated across all dose levels\n\n\n\n\n· \n\n\nStudy confirms POLB 001 potently inhibits p38 MAPK driven cytokine responses\n\n\n\n\n· \n\n\nPublication endorses significant potential of POLB 001 with the interim data anticipated from the TOPICAL trial this summer\n\n\n\n\n \nThe paper entitled, \"POLB 001, a p38 MAPK inhibitor, decreases local and systemic inflammatory responses following in vivo LPS administration in healthy volunteers: a randomised, double-blind, placebo-controlled study\" by Digna T. de Bruin, et al is available in Frontiers in Immunology, DOI: https://doi.org/10.3389/fimmu.2025.1684307\n \nThe bacterial lipopolysaccharide (\"LPS\") challenge trial was a randomised, double-blind, placebo-controlled study, examining POLB 001's ability to suppress both local and systematic inflammatory responses in healthy volunteers. Key findings include:\n \n\n\n\n\n· \n\n\nThe suppression of immune cell recruitment was most pronounced in neutrophils (72.4%-81.5%, p = 0.0091), classical monocytes (68.4%-73.6%, p = 0.0036), CD3+ T cells (56.4%-65.9%, p = 0.0047), and myeloid dendritic cells (59%-64.4%, p = 0.0174).\n\n\n\n\n· \n\n\nThe suppression of cytokine responses was most pronounced for TNF (35.3%-65.1%, p = 0.0099).\n\n\n\n\n· \n\n\nOverall, ...